Physician profile
Abigail Ogle
NPI 1154726248
$19,581.72
in general payments reported to CMS, 2019-2025
25 companies · $5,997 in 2025
The $5,997 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $4,008 · 2023: $4,644 · 2024: $4,763 · 2025: $5,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $11K · Food and Beverage: $4,119 · Education: $69.99 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $11,200.00 |
| Food and Beverage | $4,118.83 |
| Education | $69.99 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $14,400.00 | 2022-2025 | Venacure 1470 Pro |
| Amgen INC. | $2,401.52 | 2022-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $538.88 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $431.43 | 2021-2025 | Verquvo |
| Medtronic, INC. | $159.16 | 2022-2023 | Reveal Linq |
| Glaxosmithkline, LLC. | $154.89 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $151.02 | 2024-2025 | |
| Lilly USA, LLC | $137.93 | 2022-2025 | Mounjaro, Trulicity |
| Pfizer INC. | $131.32 | 2021-2025 | |
| Scpharmaceuticals INC. | $124.64 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Alnylam Pharmaceuticals INC. | $121.84 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $99.44 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $94.47 | 2024 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $75.68 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.78 | 2022 | |
| Baxter Healthcare | $70.28 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $54.00 | 2025 | Varithena Administration Pack |
| Abiomed | $49.35 | 2023-2025 | Impella |
| Smith+Nephew, INC. | $45.29 | 2022-2025 | Collagenase Santyl |
| Koya Medical, INC. | $43.76 | 2025 | Koya Medical, Dayspring |
| Abbott Laboratories | $28.76 | 2023 | Freestyle Libre 2 |
| Philips North America LLC | $27.54 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Averitas Pharma INC. | $23.71 | 2024 | Qutenza |
| Tactile Systems Technology INC | $21.40 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.